News stories about Quest Diagnostics (NYSE:DGX) have trended somewhat positive recently, Accern reports. Accern scores the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Quest Diagnostics earned a coverage optimism score of 0.13 on Accern’s scale. Accern also assigned media coverage about the medical research company an impact score of 46.6810792192875 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:
- Quest Diagnostics to Present New Insights in Autoimmune Disease at the 2017 American College of Rheumatology Meeting (finance.yahoo.com)
- Comparing Surgical Care Affiliates (SCAI) & Quest Diagnostics (DGX) (americanbankingnews.com)
- BRIEF-Quest Diagnostics acquires certain assets of California Laboratory Associates (DGX) (markets.businessinsider.com)
- Quest Diagnostics acquires California Laboratory Associates (seekingalpha.com)
A number of brokerages have recently weighed in on DGX. KeyCorp reissued a “hold” rating on shares of Quest Diagnostics in a research note on Friday, October 27th. BidaskClub upgraded shares of Quest Diagnostics from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. Canaccord Genuity raised their target price on shares of Quest Diagnostics from $100.00 to $105.00 and gave the stock a “buy” rating in a research report on Thursday, October 26th. Zacks Investment Research upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and set a $121.00 target price on the stock in a research report on Wednesday, August 2nd. Finally, ValuEngine lowered shares of Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 26th. Two analysts have rated the stock with a sell rating, fourteen have given a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $106.18.
Quest Diagnostics (DGX) opened at $94.09 on Friday. The firm has a market cap of $12.78 billion, a price-to-earnings ratio of 16.80, a price-to-earnings-growth ratio of 1.95 and a beta of 0.59. The company has a current ratio of 1.47, a quick ratio of 1.37 and a debt-to-equity ratio of 0.78.
Quest Diagnostics (NYSE:DGX) last announced its earnings results on Thursday, October 19th. The medical research company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.35 by $0.04. The firm had revenue of $1.93 billion during the quarter, compared to analyst estimates of $1.92 billion. Quest Diagnostics had a return on equity of 15.53% and a net margin of 8.82%. The business’s revenue was up 2.4% compared to the same quarter last year. During the same period last year, the firm posted $1.37 EPS. research analysts expect that Quest Diagnostics will post 5.65 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Wednesday, October 18th. Shareholders of record on Tuesday, October 3rd were issued a $0.45 dividend. The ex-dividend date of this dividend was Monday, October 2nd. This represents a $1.80 annualized dividend and a dividend yield of 1.91%. Quest Diagnostics’s payout ratio is currently 37.74%.
In related news, CEO Stephen H. Rusckowski sold 53,933 shares of Quest Diagnostics stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $108.16, for a total transaction of $5,833,393.28. Following the sale, the chief executive officer now directly owns 220,049 shares in the company, valued at $23,800,499.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Chairman Stephen H. Rusckowski sold 59,235 shares of the business’s stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $108.16, for a total value of $6,406,857.60. Following the completion of the sale, the chairman now directly owns 220,049 shares in the company, valued at $23,800,499.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 160,396 shares of company stock worth $17,343,852. 1.75% of the stock is currently owned by insiders.
TRADEMARK VIOLATION WARNING: This story was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.com-unik.info/2017/11/04/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-quest-diagnostics-dgx-stock-price.html.
About Quest Diagnostics
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through two businesses: Diagnostic Information Services and Diagnostic Solutions. The Diagnostic Information Services business develops and delivers diagnostic testing information and services, providing insights that empower and enable a range of customers, including patients, clinicians, hospitals, integrated delivery networks (IDNs), health plans, employers and accountable care organizations (ACOs).
What are top analysts saying about Quest Diagnostics Incorporated? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Quest Diagnostics Incorporated and related companies.